ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FHTX / insiders
HURA (32) BGM (37) CATX (33) OGI (45) ⌘ Pro Terminal →

Foghorn Therapeutics Inc. (FHTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.13 +2.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.14

Foghorn Therapeutics Inc. (FHTX) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $123.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FHTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FHTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Foghorn Therapeutics Inc. (NASDAQ: FHTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $2.13 (+2.40% 1D, market cap $123.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FHTX ranks #1001 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FHTX compare to HURA and BGM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FHTX carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HURA (TuHURA Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $123.0M) and BGM (BGM Group Ltd. (Class A)) posts a D- grade (37/100 RQD, P/E N/A, ROIC —, cap $127.4M). Among the 5-stock peer group, FHTX leads on earnings multiple (N/A) while FHTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FHTX?
▼

Per FHTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822462), Foghorn Therapeutics Inc. generated $30.9M in revenue (+36.8% YoY), -$74.3M in net income, and -$86.1M in free cash flow against $198.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.14 (+0.24%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510018
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (3)Whales (3)SEC (5)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.8% Base Target
$8 Bull$2 Base$1 Bear
📬 FREE FHTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FHTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (18/100 Composite)
🔍 WHY FHTX SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (28% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (28% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 30.4 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
15
Grade E$1.95-4.1% Next Q
Q2 (-2Q)
16
Grade E$1.87+9.6% Next Q
Q3 (-1Q)
18
Grade E$2.05+3.9% Next Q
Current
18
Grade E$2.13-12.2% Hist 90D α
Trajectory: E (15) → E (18)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FHTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FHTX currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.50) and Max Pain ($2.24) forces dealer call-delta covering toward $7.99.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FHTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FHTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 18%NO 82%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

FHTX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (FHTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on FHTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FHTX)

  • ✓Walkthrough of FHTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FHTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.49%📐 HORIZONTAL RANGE
2026-11-03O $2.09H $2.13L $2.08C $2.13VOL 555.6K
RES: $9.32SUP: $0.45SMA50: $3.50SMA200: $4.69
$8.02$6.33$4.64$2.95$1.27RES $9.32SUP $0.45$2.132026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FHTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FHTX Butterfly Map → + Track FHTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +36.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FHTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FHTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FHTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FHTX)

Health Care Rank #1001 of 1015 ⚔️ HURA vs FHTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FHTX vs. HURA, BGM, CATX, OGI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Foghorn Therapeutics Inc. (FHTX) ranks #1001 by composite RQD confidence (18/100, grade E) and #628 by equity capitalization ($123.5M). Within this direct 5-issuer industry benchmark cohort, FHTX leads on earnings valuation at N/A trailing P/E, while FHTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OGI currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with FHTX at 18/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FHTX ACTIVE
Foghorn Therapeutics Inc.
E 18/100 — — -35.0% +2.40% $123.5M Benchmark Subject
HURA
TuHURA Biosciences Inc.
E 32/100 — — -35.0% -10.88% $123.0M /hura-vs-fhtx →
BGM
BGM Group Ltd. (Class A)
D- 37/100 — 16.6% — 0.00% $127.4M /bgm-vs-fhtx →
CATX
Perspective Therapeutics Inc.
E 33/100 — — -35.0% -9.56% $131.3M /catx-vs-fhtx →
OGI
Organigram Global Inc.
D 45/100 — — — +3.43% $131.6M /ogi-vs-fhtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001822462 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Foghorn Therapeutics Inc. (FHTX) reported GAAP revenue of $30.9M (+36.8% vs. FY2024 revenue of $22.6M , and -9.5% cumulative change since FY2023) , GAAP net income of -$74.3M, operating cash flow of -$86.1M, and free cash flow of -$86.1M (+15.0% YoY). On the balance sheet, FHTX closed FY2025 with $198.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $30.9M -$74.3M -$86.1M -$86.1M $198.1M —
FY2024 (FY) 2024-12-31 $22.6M -$86.6M -$100.4M -$101.3M $284.0M —
FY2023 (FY) 2023-12-31 $34.2M -$98.4M -$118.1M -$118.1M — —

3. FHTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FHTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Foghorn Therapeutics Inc. (NASDAQ: FHTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $2.13 (+2.40% 1D, market cap $123.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FHTX ranks #1001 in composite RQD confidence.

How does FHTX compare to HURA and BGM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FHTX carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HURA (TuHURA Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $123.0M) and BGM (BGM Group Ltd. (Class A)) posts a D- grade (37/100 RQD, P/E N/A, ROIC —, cap $127.4M). Among the 5-stock peer group, FHTX leads on earnings multiple (N/A) while FHTX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FHTX?

Per FHTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822462), Foghorn Therapeutics Inc. generated $30.9M in revenue (+36.8% YoY), -$74.3M in net income, and -$86.1M in free cash flow against $198.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FHTX trading relative to its 50-day, 200-day, and 52-week technical levels?

FHTX last traded at $2.13 (+2.40% on volume of 715,168 shares), positioning the stock -39.14% below its 50-day simple moving average ($3.50) and -54.58% below its 200-day simple moving average ($4.69). Across its 52-week range of $1.79 to $7.61, FHTX sits at the 5.8% percentile with a 14-day RSI of 30.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.86 to $2.40).

Direct Sub-Reports: FHTX RQD Cockpit FHTX 12M Forecast FHTX Earnings & Move FHTX Dividends & DRIP FHTX Insiders & 13F FHTX Whale Options FHTX Profit Sankey FHTX News & Why
ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ SEC XBRL & RQD VERIFIED

FHTX — Foghorn Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Foghorn Therapeutics Inc. (FHTX) earns a live Roarable RQD composite score of 18/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.13 (+2.40% 1D, market capitalization $123.5M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Foghorn Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. The company reported revenue in each of the three listed fiscal years, though the source does not identify its sources of revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Foghorn Therapeutics Inc. (FHTX) reported $30.9M in annual revenue (up from $22.6M in FY2024, +36.8% YoY) and -$74.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($34.2M revenue, -$98.4M net income) through FY2025, FHTX scaled operating cash flow to -$86.1M and free cash flow to -$86.1M, backed by $198.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 18/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.79 – $7.61 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream links and no sector correlation data. The news feed's references to Eli Lilly, an exit from FHD-909, and a shift to preclinical assets suggest a partner-dependency question, but the source does not establish supply-chain relationships.

  • Key Question #1: Can FHTX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $30.9M and free cash flow of -$86.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FHTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FHTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Foghorn Therapeutics Inc. (FHTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FHTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FHTX Bull vs. Bear Conversation Board — What's Your Call at $2.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FHTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FHTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $2.68 (+28.8%)
📌 Pinned Debate

Recent coverage flags the company as expected to beat earnings estimates, and reported cash rose to $80.9M in FY 2025.

The street is overcomplicating Foghorn Therapeutics Inc. (FHTX). Recent coverage flags the company as expected to beat earnings estimates, and reported cash rose to $80.9M in FY 2025.. With an RQD score of 18/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $2.25.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 3/20 institutional whale-flow stock at $2.08 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.66 (-20.2%)
Spot @ $2.08

ROIC of -35%, FCF of -$86.1M in FY 2025, an Altman Z-Score of 0.2, and downgrades plus investor investigations weigh on the outlook.

Careful chasing FHTX at $2.08. ROIC of -35%, FCF of -$86.1M in FY 2025, an Altman Z-Score of 0.2, and downgrades plus investor investigations weigh on the outlook.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.66 on multiple compression.

LIVE TAPE